newsfilter
← Latest News
GlobeNewswire·

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

  • Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone increased his holdings by purchasing 15,000 common shares at $1.11 per share.
  • Cerrone's total holding now stands at 44,772,230 common shares, representing 34.89% of the company's issued share capital.
  • The company's lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate T regulatory cells.
  • In an open-label Expanded Access Program (NCT06802328), 14 patients with non-active secondary progressive multiple sclerosis showed disease improvement or stability within six months.
  • Foralumab is currently being evaluated in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter trial for non-active secondary progressive multiple sclerosis (NCT06292923).
  • Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development.
  • Tiziana Life Sciences utilizes a patented intranasal delivery approach intended to improve efficacy, safety, & tolerability compared to intravenous immunotherapy.
  • The company's alternative route immunotherapy technology has several patent applications pending & supports a broad pipeline.